What's breaking now, across thousands of outlets.
Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
Air crew have more radiation-related cancer deaths than any other profession, write Vishal R. Patel, Christopher Worsham, and Anupam B. Jena.
Health Canada has authorized a drug to treat moderate to severe hot flashes and night sweats in breast cancer patients. Elinzanetant, also known by the brand name Lynkuet, was first approved in July…
EyePoint’s experimental eye treatment came up short of Eylea, the current go-to option for wet age-related macular degeneration, according to results of a Phase 3 trial.
A new study tracked more than 500 teens showing that relationships between them and their pet dogs helped with stress and anxiety.
